title: Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis.
authors.forename: J D
authors.initials: JD
authors.lastname: Cohen
authors.forename: S
authors.initials: S
authors.lastname: Zaltni
authors.forename: M J
authors.initials: MJ
authors.lastname: Kaiser
authors.forename: M C
authors.initials: MC
authors.lastname: Bozonnat
authors.forename: C
authors.initials: C
authors.lastname: Jorgensen
authors.forename: J P
authors.initials: JP
authors.lastname: Daurès
authors.forename: J
authors.initials: J
authors.lastname: Sany
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate